Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab

Abstract

Background: There is a scarcity of real-world data on treatment patterns and outcomes among advanced melanoma patients treated with immunotherapies including ipilimumab, an anti-CTLA-4 antibody approved since 2011. Objective: To evaluate ipilimumab and postipilimumab treatment patterns and outcomes among patients with advanced melanoma in Australia, Germany, Italy and Spain, following regulatory approval. Methods: Retrospective multicentre, multinational, observational chart review study. Data were extracted from the start of ipilimumab therapy until the end of at least 40 weeks of follow-up, or death. Results: Data from 371 patients (Australia, 103; Germany, 152; Italy, 76; Spain, 40) were ..